75 related articles for article (PubMed ID: 15922862)
41. A report of early cytogenetic response to imatinib in two patients with chronic myeloid leukemia at accelerated phase and carrying the e19a2 BCR-ABL transcript.
Li X; Yang J; Chen X; Liu J; Li H; Zheng J; He Y; Chen Z; Huang S
Cancer Genet Cytogenet; 2007 Jul; 176(2):166-8. PubMed ID: 17656262
[TBL] [Abstract][Full Text] [Related]
42. Detection of survivin-expressing circulating cancer cells (CCCs) in peripheral blood of patients with gastric and colorectal cancer reveals high risks of relapse.
Yie SM; Lou B; Ye SR; Cao M; He X; Li P; Hu K; Rao L; Wu SM; Xiao HB; Gao E
Ann Surg Oncol; 2008 Nov; 15(11):3073-82. PubMed ID: 18670822
[TBL] [Abstract][Full Text] [Related]
43. Bone marrow derived mesenchymal stem cells from chronic myeloid leukemia t(9;22) patients are devoid of Philadelphia chromosome and support cord blood stem cell expansion.
Jootar S; Pornprasertsud N; Petvises S; Rerkamnuaychoke B; Disthabanchong S; Pakakasama S; Ungkanont A; Hongeng S
Leuk Res; 2006 Dec; 30(12):1493-8. PubMed ID: 16839603
[TBL] [Abstract][Full Text] [Related]
44. Differential molecular response of the transcripts B2A2 and B3A2 to imatinib mesylate in chronic myeloid leukemia.
de Lemos JA; de Oliveira CM; Scerni AC; Bentes AQ; Beltrão AC; Bentes IR; Azevedo TC; Maradei-Pereira LM
Genet Mol Res; 2005 Dec; 4(4):803-11. PubMed ID: 16475128
[TBL] [Abstract][Full Text] [Related]
45. [Secondary chromosomic changes in patients with chronic myeloid leukemia in a reference hospital in Northeastern Mexico].
Dávila-Rodríguez MI; Cerda-Flores RM; Leal-Garza CH; Arana-Trejo RM; Báez-de la Fuente E; Cortés-Gutiérrez EI
Gac Med Mex; 2004; 140(6):589-92. PubMed ID: 15633564
[TBL] [Abstract][Full Text] [Related]
46. Survivin expression in the progression of chronic myeloid leukemia: a sequential study in 16 patients.
Hernández-Boluda JC; Bellosillo B; Vela MC; Colomer D; Alvarez-Larrán A; Cervantes F
Leuk Lymphoma; 2005 May; 46(5):717-22. PubMed ID: 16019509
[TBL] [Abstract][Full Text] [Related]
47. [Blood levels of the adhesion molecules ICAM-1 and VCAM-1 in patients with chronic myeloid leukemia during remission and exacerbation].
Kiersnowska-Rogowska B; Parfieńczyk A; Rogowski F
Pol Merkur Lekarski; 2004 Mar; 16(93):240-4. PubMed ID: 15190600
[TBL] [Abstract][Full Text] [Related]
48. [Expression of XIAP gene in chronic myeloid leukemia and its clinical significance].
Wang SG; Guan HZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):321-3. PubMed ID: 21518480
[TBL] [Abstract][Full Text] [Related]
49. [The expression and clinical significance of survivin gene in leukemia].
Wang Y; Lin FR; Ren JH; Zhang JN; Chen J
Zhonghua Nei Ke Za Zhi; 2006 Aug; 45(8):628-30. PubMed ID: 17074144
[TBL] [Abstract][Full Text] [Related]
50. A complex karyotype in promyelocytic-like blastic transformation of Ph-positive chronic myeloid leukemia.
Panani AD; Stamouli M; Harhalakis N; Nikiforakis M; Roussos Ch
Cancer Genet Cytogenet; 2005 Apr; 158(1):92-4. PubMed ID: 15771913
[No Abstract] [Full Text] [Related]
51. [Behavior of the guinea pig biological test in relation to inoculation of material corresponding to different phases of the disease from a subject with chronic myeloid leukemia].
NEGRONI G; TOLU A
Boll Soc Ital Biol Sper; 1951; 27(7-8):1246-7. PubMed ID: 14904652
[No Abstract] [Full Text] [Related]
52. Characterization of anti-human interleukin-18 (IL-18)/interferon-gamma-inducing factor (IGIF) monoclonal antibodies and their application in the measurement of human IL-18 by ELISA.
Taniguchi M; Nagaoka K; Kunikata T; Kayano T; Yamauchi H; Nakamura S; Ikeda M; Orita K; Kurimoto M
J Immunol Methods; 1997 Aug; 206(1-2):107-13. PubMed ID: 9328573
[TBL] [Abstract][Full Text] [Related]
53. Isoalantolactone mediates the degradation of BCR-ABL protein in imatinib-resistant CML cells by down-regulating survivin.
Yin SS; Chen C; Liu Z; Liu SL; Guo JH; Zhang C; Zhang QW; Gao FH
Cell Cycle; 2023 Jun; 22(12):1407-1420. PubMed ID: 37202916
[TBL] [Abstract][Full Text] [Related]
54. Dysregulation of LINC00470 and METTL3 promotes chemoresistance and suppresses autophagy of chronic myelocytic leukaemia cells.
Lai X; Wei J; Gu XZ; Yao XM; Zhang DS; Li F; Sun YY
J Cell Mol Med; 2021 May; 25(9):4248-4259. PubMed ID: 33749070
[TBL] [Abstract][Full Text] [Related]
55. Targeting the MAPK/ERK and PI3K/AKT Signaling Pathways Affects NRF2, Trx and GSH Antioxidant Systems in Leukemia Cells.
Jasek-Gajda E; Jurkowska H; Jasińska M; Lis GJ
Antioxidants (Basel); 2020 Jul; 9(7):. PubMed ID: 32709140
[TBL] [Abstract][Full Text] [Related]
56. Phase I study of the novel Cdc2/CDK1 and AKT inhibitor terameprocol in patients with advanced leukemias.
Tibes R; McDonagh KT; Lekakis L; Bogenberger JM; Kim S; Frazer N; Mohrland S; Bassett D; Garcia R; Schroeder K; Shanmugam V; Carpten J; Hagelstrom RT; Beaudry C; Von Hoff D; Shea TC
Invest New Drugs; 2015 Apr; 33(2):389-96. PubMed ID: 25523151
[TBL] [Abstract][Full Text] [Related]
57. Multidrug resistance in chronic myeloid leukaemia: how much can we learn from MDR-CML cell lines?
Rumjanek VM; Vidal RS; Maia RC
Biosci Rep; 2013 Nov; 33(6):. PubMed ID: 24070327
[TBL] [Abstract][Full Text] [Related]
58. The Interface between BCR-ABL-Dependent and -Independent Resistance Signaling Pathways in Chronic Myeloid Leukemia.
Nestal de Moraes G; Souza PS; Costas FC; Vasconcelos FC; Reis FR; Maia RC
Leuk Res Treatment; 2012; 2012():671702. PubMed ID: 23259070
[TBL] [Abstract][Full Text] [Related]
59. Carbenoxolone induces apoptosis and inhibits survivin and survivin-ΔEx3 genes expression in human leukemia K562 cells.
Moosavi MA; Moasses Ghafary S; Asvadi-Kermani I; Hamzeiy H; Rahmati M; Ahmadi AH; Nikanfar A; Sanaat Z; Asadi-Khiavi M
Daru; 2011; 19(6):455-61. PubMed ID: 23008692
[TBL] [Abstract][Full Text] [Related]
60. Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells.
Carter BZ; Mak DH; Schober WD; Cabreira-Hansen M; Beran M; McQueen T; Chen W; Andreeff M
Blood; 2006 Feb; 107(4):1555-63. PubMed ID: 16254145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
